Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
G. Singh.
Recent considerations in nonsteroidal anti-inflammatory drug gastropathy.
Am J Med, 105 (1998), pp. 31S-38S
[2.]
E. Rahme, L. Joseph, S.X. Kong, D.J. Watson, J. LeLorier.
Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population.
Arthritis Rheum, 43 (2000), pp. 917-924
[3.]
W.E. Smalley, M.R. Griffin, R.L. Fought, W.A. Ray.
Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs.
J Gen Intern Med, 11 (1996), pp. 461-469
[4.]
A. Lanas, M. Andreu, E. Bajador, L. Rodrigo, S. Lorente, A. López-Morante, et al.
Estudio nacional sobre la mortalidad debida a complicaciones gastrointestinales asociadas al consumo de AINE.
Gastroenterol Hepatol, 27 (2004), pp. 185
[5.]
A. Lanas.
Cost stratification of nonsteroidal anti-inflammatory drug-associated gastrointestinal side effects.
Med Clin (Barc), 114 (2000), pp. 46-53
[6.]
A. Lanas, E. Martín-Mola, J. Ponce, F. Navarro, J.M. Pique, F.J. Blanco.
Clinical strategy to prevent the gastrointestinal adverse effects of nonsteroidal anti-inflammatory agents.
Gastroenterol Hepatol, 26 (2003), pp. 485-502
[7.]
D. Heresbach, J.L. Raoul, J.F. Bretagne, J. Minet, P.Y. Donnio, M.P. Ramee, et al.
Helicobacter pylori: a risk and severity factor of non-steroidal anti-inflammatory drug induced gastropathy.
Gut, 33 (1992), pp. 1608-1611
[8.]
L. Santucci, S. Fiorucci, L. Patoia, F.M. Di Matteo, P.M. Brunori, A. Morelli.
Severe gastric mucosal damage induced by NSAIDs in healthy subjects is associated with Helicobacter pylori infection and high levels of serum pepsinogens.
Dig Dis Sci, 40 (1995), pp. 2074-2080
[9.]
D.Y. Graham, M.D. Lidsky, A.M. Cox, D.J. Evans Jr, D.G. Evans, L. Alpert, et al.
Long-term nonsteroidal antiinflammatory drug use and Helicobacter pylori infection.
Gastroenterology, 100 (1991), pp. 1653-1657
[10.]
D.S. Loeb, N.J. Talley, D.A. Ahlquist, H.A. Carpenter, A.R. Zinsmeister.
Long-term nonsteroidal anti-inflammatory drug use and gastroduodenal injury: the role of Helicobacter pylori.
Gastroenterology, 102 (1992), pp. 1899-1905
[11.]
S. Santolaria, A. Lanas, R. Benito, M. Pérez-Aisa, M. Montoro, R. Sainz.
Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users.
Aliment Pharmacol Ther, 13 (1999), pp. 1511-1518
[12.]
C. Aalykke, J.M. Lauritsen, J. Hallas, S. Reinholdt, K. Krogfelt, K. Lauritsen.
Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: a case-control study.
Gastroenterology, 116 (1999), pp. 1305-1309
[13.]
J.Q. Huang, S. Sridhar, R.H. Hunt.
Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a metaanalysis.
Lancet, 359 (2002), pp. 14-22
[14.]
F.K. Chan, J.J. Sung, S.C. Chung, K.F. To, M.Y. Yung, V.K. Leung, et al.
Randomised trial of eradication of Helicobacter pylori before non-steroidal antiinflammatory drug therapy to prevent peptic ulcers.
Lancet, 350 (1997), pp. 975-979
[15.]
F.K. Chan, K.F. To, J.C. Wu, M.Y. Yung, W.K. Leung, T. Kwok, et al.
Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial.
Lancet, 359 (2002), pp. 9-13
[16.]
J. Labenz, A.L. Blum, W.W. Bolten, B. Dragosics, W. Rosch, M. Stolte, et al.
Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial.
Gut, 51 (2002), pp. 329-335
[17.]
C.J. Hawkey, Z. Tulassay, L. Szczepanski, C.J. Van Rensburg, A. Filipowicz- Sosnowska, A. Lanas, et al.
Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention.
Lancet, 352 (1998), pp. 1016-1021
[18.]
K.C. Lai, C.S. Lau, W.Y. Ip, B.C. Wong, W.M. Hui, W.H. Hu, et al.
Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial.
Aliment Pharmacol Ther, 17 (2003), pp. 799-805
[19.]
Vergara M, Catalán M, Gisbert JP, Calvet X. Meta-analysis: role of Heliobacter pylori eradication in the prevention of peptic ulcer in NSAID Users. Aliment Pharmacol Ther. 2005 (En prensa).
[20.]
F.K. Chan, S.C. Chung, B.Y. Suen, Y.T. Lee, W.K. Leung, V.K. Leung, et al.
Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen.
N Engl J Med, 344 (2001), pp. 967-973
[21.]
K.C. Lai, S.K. Lam, K.M. Chu, W.M. Hui, K.F. Kwok, B.C. Wong, et al.
Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti–inflammatory drug users–a randomized trial.
Aliment Pharmacol Ther, 18 (2003), pp. 829-836
[22.]
K.C. Lai, S.K. Lam, K.M. Chu, B.C. Wong, W.M. Hui, W.H. Hu, et al.
Lansoprazole for the prevention of recurrences of ulcer complications from longterm low-dose aspirin use.
N Engl J Med, 346 (2002), pp. 2033-2038
[23.]
E.F. Verdu, D. Armstrong, J.P. Idstrom, J. Labenz, M. Stolte, G. Borsch, et al.
Intragastric pH during treatment with omeprazole: role of Helicobacter pylori and H. pylori-associated gastritis.
Scand J Gastroenterol, 31 (1996), pp. 1151-1156
[24.]
J. Labenz, B. Tillenburg, U. Peitz, E. Verdu, M. Stolte, G. Borsch, et al.
Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer.
Gut, 41 (1997), pp. 33-36
[25.]
J. Labenz, B. Tillenburg, U. Peitz, G. Borsch, J.P. Idstrom, E. Verdu, et al.
Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients.
Am J Gastroenterol, 92 (1997), pp. 576-581
[26.]
C.J. Hawkey, J.A. Karrasch, L. Szczepanski, D.G. Walker, A. Barkun, A.J. Swannell, et al.
Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.
N Engl J Med, 338 (1998), pp. 727-734
[27.]
N.D. Yeomans, Z. Tulassay, L. Juhasz, I. Racz, J.M. Howard, C.J. Van Rensburg, et al.
A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group.
N Engl J Med, 338 (1998), pp. 719-726
[28.]
C.J. Hawkey, J. Naesdal, I. Wilson, G. Langstrom, A.J. Swannell, R.A. Peacock, et al.
Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugs.
Gut, 51 (2002), pp. 336-343
[29.]
D.Y. Graham.
Critical effect of Helicobacter pylori infection on the effectiveness of omeprazole for prevention of gastric or duodenal ulcers among chronic NSAID users.
Helicobacter, 7 (2002), pp. 1-8
[30.]
A.B. Thomson, M. Keelan, R. Lastiwka, S. Appelman-Eszcuck, L. Zuk, L. Drozdowski, et al.
Acid inhibitory potency of twice a day omeprazole is not affected by eradication of Helicobacter pylori in healthy volunteers.
Helicobacter, 8 (2003), pp. 46-58
[31.]
J.M. Scheiman, N. Vakil, C.J. Hawkey, N.D. Yeomans, N.J. Talley, F.K. Chan, et al.
Esomeprazole prevents gastric and duodenal ulcers in at-risk patients on continuous non-selective or Cox-2 selective NSAID therapy.
Gastroenterology, 126 (2004), pp. A-82
[32.]
L. Laine, C. Bombardier, C.J. Hawkey, B. Davis, D. Shapiro, C. Brett, et al.
Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis.
Gastroenterology, 123 (2002), pp. 1006-1012
[33.]
F.K. Chan, L.C. Hung, B.Y. Suen, J.C. Wu, K.C. Lee, V.K. Leung, et al.
Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.
N Engl J Med, 347 (2002), pp. 2104-2110
[34.]
A. Ford, B. Delaney, D. Forman, P. Moayyedi.
Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients.
Cochrane Database Syst Rev, (2003), pp. CD003840
[35.]
J. Gisbert, S. Khorrami, F. Carballo, X. Calvet, E. Gené, J. Domínguez-Muñoz.
H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer.
Cochrane Database Syst Rev, 4 (2003), pp. CD004062
[36.]
A. Lanas, L. Rodrigo, J.L. Márquez, E. Bajador, F. Pérez-Roldan, J. Cabrol, et al.
Low frequency of upper gastrointestinal complications in a cohort of high-risk patients taking low-dose aspirin or NSAIDS and omeprazole.
Scand J Gastroenterol, 38 (2003), pp. 693-700
[37.]
L. Laine.
Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient.
Gastroenterology, 120 (2001), pp. 594-606
Copyright © 2005. Elsevier España S.L. Barcelona
